- Home
- UCL vs FBRX Comparison
UCL vs FBRX Comparison
Compare UCL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- FBRX
- Stock Information
- Founded
- UCL 2014
- FBRX N/A
- Country
- UCL Hong Kong
- FBRX United States
- Employees
- UCL N/A
- FBRX N/A
- Industry
- UCL Telecommunications Equipment
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- FBRX Health Care
- Exchange
- UCL Nasdaq
- FBRX Nasdaq
- Market Cap
- UCL 144.5M
- FBRX 154.5M
- IPO Year
- UCL 2020
- FBRX N/A
- Fundamental
- Price
- UCL $2.18
- FBRX $14.38
- Analyst Decision
- UCL
- FBRX Strong Buy
- Analyst Count
- UCL 0
- FBRX 3
- Target Price
- UCL N/A
- FBRX $68.00
- AVG Volume (30 Days)
- UCL 26.6K
- FBRX 99.1K
- Earning Date
- UCL 11-25-2025
- FBRX 11-13-2025
- Dividend Yield
- UCL N/A
- FBRX N/A
- EPS Growth
- UCL N/A
- FBRX N/A
- EPS
- UCL 0.02
- FBRX N/A
- Revenue
- UCL $89,277,000.00
- FBRX N/A
- Revenue This Year
- UCL N/A
- FBRX N/A
- Revenue Next Year
- UCL $20.86
- FBRX N/A
- P/E Ratio
- UCL $95.30
- FBRX N/A
- Revenue Growth
- UCL 3.72
- FBRX N/A
- 52 Week Low
- UCL $0.80
- FBRX $4.11
- 52 Week High
- UCL $4.19
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- UCL 45.45
- FBRX 58.01
- Support Level
- UCL $2.15
- FBRX $11.00
- Resistance Level
- UCL $2.39
- FBRX $12.36
- Average True Range (ATR)
- UCL 0.13
- FBRX 1.04
- MACD
- UCL 0.04
- FBRX 0.01
- Stochastic Oscillator
- UCL 48.28
- FBRX 72.93
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).